Author headshot

Kemi Olugemo, MD, FAAN

Olugemo is vice president, Global Clinical Development at Ultragenyx Pharmaceutical.

Most recent by Kemi Olugemo, MD, FAAN

SPONSORED CONTENT
May 20, 2024
3 min watch
Save

VIDEO: ‘Clinically significant’ cognitive improvement found with Angelman syndrome drug

DENVER — Treatment with a novel therapeutic led to clinically significant improvement in cognition for young persons with Angelman syndrome, Kemi Olugemo, MD, FAAN, said in this Healio video at the American Academy of Neurology annual meeting.